These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 2710476)
1. Evaluation of the ovarian cancer antigen, Ca-125, as a tumor marker. Onetto M; Bruzzone M; Conte PF; Ruvolo M; Conio A; Chiara S; Falcone A; Bentivoglio G; Serra GE; Paganuzzi M Oncology; 1989; 46(2):117-22. PubMed ID: 2710476 [TBL] [Abstract][Full Text] [Related]
2. CA 15-3 serum levels in ovarian cancer. Scambia G; Benedetti Panici P; Baiocchi G; Perrone L; Greggi S; Di Roberto P; Mancuso S Oncology; 1988; 45(3):263-7. PubMed ID: 3163419 [TBL] [Abstract][Full Text] [Related]
3. [Serum level of the tumor marker CA 125 before second-look laparatomy in primary epithelial ovarian cancer in relation to intraoperative findings]. Meden H; Rath W; Teichmann A; Kuhn W Onkologie; 1989 Oct; 12(5):217-20. PubMed ID: 2685687 [TBL] [Abstract][Full Text] [Related]
4. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer. Castelli M; Battaglia F; Scambia G; Panici PB; Ferrandina G; Mileo AM; Mancuso S; Ferrini U Oncology; 1991; 48(1):13-7. PubMed ID: 1987493 [TBL] [Abstract][Full Text] [Related]
5. Clinical usefulness of serum sialyl SSEA-1 antigen levels in patients with epithelial ovarian cancer. Comparative effectiveness of sialyl SSEA-1 and CA 125. Kobayashi H; Kawashima Y Gynecol Obstet Invest; 1990; 30(1):52-8. PubMed ID: 1977666 [TBL] [Abstract][Full Text] [Related]
6. CA-125 monitoring in the management of ovarian cancer. Bruzzone M; Onetto M; Campora E; Chiara S; Oliva C; Guido T; Merlini L; Parodi S; Bentivoglio G; Ventrella W Anticancer Res; 1990; 10(5A):1353-9. PubMed ID: 2241112 [TBL] [Abstract][Full Text] [Related]
7. Studies on angiogenesis in the benign and malignant ovarian neoplasms with the use of color and pulsed Doppler sonography and serum CA-125, CA-19.9, CA-72.4 and vascular endothelial growth factor measurements. Czekierdowski A Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):113-31. PubMed ID: 12898913 [TBL] [Abstract][Full Text] [Related]
8. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group]. Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323 [TBL] [Abstract][Full Text] [Related]
9. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma. Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392 [TBL] [Abstract][Full Text] [Related]
10. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers. Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816 [TBL] [Abstract][Full Text] [Related]
11. Measurement of the ovarian cancer-associated antigen CA 125 in monitoring tumor burden and response to chemotherapy. Quaranta M; Coviello M; Donadeo A; Rella C; Lorusso V; Micelli G; Lucarelli C Tumori; 1991 Apr; 77(2):167-9. PubMed ID: 2048231 [TBL] [Abstract][Full Text] [Related]
12. A comparative study of mucin-like carcinoma-associated antigen (MCA), CA 125, CA 19-9 and CEA in patients with ovarian cancer. Koelbl H; Schieder K; Neunteufel W; Bieglmayer C Neoplasma; 1989; 36(4):473-8. PubMed ID: 2770933 [TBL] [Abstract][Full Text] [Related]
13. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma. Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363 [TBL] [Abstract][Full Text] [Related]
14. Combined evaluation of serum CA 125 and CAM 29 in patients with epithelial ovarian cancer. Ferdeghini M; Gadducci A; Prontera C; Malagnino G; Annicchiarico C; Prato B; Bianchi R; Fioretti P Tumour Biol; 1992; 13(5-6):287-93. PubMed ID: 1290026 [TBL] [Abstract][Full Text] [Related]
15. [Usefulness of osteopontin (OPN) determinations in ovarian cancer patients who underwent first-line chemotherapy]. Mrochem-Kwarciak J; Mrochen-Domin I; Wojcieszek A; Deja R; Chmura A; Masłyk B; Nowara E; Kaleta B; Kołosza Z; Bartnik W Ginekol Pol; 2011 Dec; 82(12):911-7. PubMed ID: 22384627 [TBL] [Abstract][Full Text] [Related]
16. Alpha 1-acid glucoprotein in ovarian cancer with a reference to immunosuppressive acidic protein and cancer antigen 125. Mogensen O; Mogensen B; Jakobsen A Cancer; 1989 Nov; 64(9):1867-71. PubMed ID: 2477138 [TBL] [Abstract][Full Text] [Related]
17. CA 125 in ovarian cancer. van der Burg ME; Lammes FB; Verweij J Neth J Med; 1992 Feb; 40(1-2):36-51. PubMed ID: 1579185 [TBL] [Abstract][Full Text] [Related]
18. A new biomarker in monitoring breast cancer: CA 549. Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875 [TBL] [Abstract][Full Text] [Related]
19. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma. Meisel M; Straube W; Weise J; Burkhardt B Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659 [TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of circulating serum sialyl Tn antigen levels in patients with epithelial ovarian cancer. Kobayashi H; Terao T; Kawashima Y J Clin Oncol; 1991 Jun; 9(6):983-7. PubMed ID: 1851822 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]